Eli Lilly, Pfizer, Merck among Big Pharma losers in China's latest round of procurement bidding
The Pharma Data
AUGUST 20, 2020
The latest results underscore that large pharma companies are making a “strategic retreat from some of their older drugs,” in China, ICBC International Research analyst Zhang Jialin said, as quoted by Bloomberg; instead, they’re focusing on growing market share for newer medicines. It’s not a completely unforeseen shift, though.